357M-1

TCL1 (MRQ-7) Mouse Monoclonal Antibody

• UNSPSC Code: 12352203
• NACRES: NA.41

Properties

• biological source: mouse
• Quality Level: 100; 500
• conjugate: unconjugated
• antibody form: culture supernatant
• antibody product type: primary antibodies
• clone: MRQ-7, monoclonal
• description: For In Vitro Diagnostic Use in Select Regions (See Chart)
• form: buffered aqueous solution
• species reactivity: human
• packaging: vial of 0.1 mL concentrate (357M-14); vial of 0.5 mL concentrate (357M-15); bottle of 1.0 mL predilute (357M-17); vial of 1.0 mL concentrate (357M-16); bottle of 7.0 mL predilute (357M-18)
• manufacturer/tradename: Cell Marque^®
• technique(s): immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500
• isotype: IgG
• control: B-cell lymphoma, tonsil
• shipped in: wet ice
• storage temp.: 2-8°C
• visualization: cytoplasmic, nuclear
• Gene Information: human ... TCL1A(8115)

Description

General description

T-cell leukemia/lymphoma protein 1 (TCL1, TCL1A, p14TCL1) is a 14 kDa product of the TCL1 gene that is involved in T-cell prolymphocytic leukemia (T-PLL). TCL1 protein is normally found in the nucleus and cytoplasm of lymphoid lineage cells during early embryogenesis. Chromosomal translocations may lead to overexpression of TCL1, resulting in T-cell leukemia and B-cell lymphoma. TCL1 binds to a novel site in the pleckstrin homology (PH) domain, resulting in activation and nuclear translocation of Akt by overexpressed TCL1 which may promote an anti-apoptotic response; this may normally serve to promote growth during development but may lead to malignancy when TCL1 is overexpressed. TCL1 is expressed in differentiated B-cells under both reactive and neoplastic conditions, antigen committed B-cells, and in germinal center B-cells. TCL1 is down-regulated in the latest stage of B-cell differentiation. TCL1 is overexpressed in Burkitt lymphoma, the majority of AIDS-related non-Hodgkin lymphoma-designated immunoblastic plasmacytoid lymphoma, lymphoblastic lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, and primary cutaneous B-cell lymphoma. Therefore, the most useful application of anti-TCL1 is the discrimination of B-cell lymphomas from T-cell lymphomas, CD30+ anaplastic large cell lymphomas, multiple myeloma, and marginal zone B-cell lymphoma.

Quality

IVD

IVD

IVD

RUO

Linkage

TCL1 Positive Control Slides, Product No. 357S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Preparation Note

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Other Notes

For Technical Service please contact: 800-665-7284 or email: [email protected]

Legal Information

Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany